InvestorsHub Logo
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

Re: None

Wednesday, 11/16/2011 6:08:04 PM

Wednesday, November 16, 2011 6:08:04 PM

Post# of 233
Alnylam Pharma grants InterfeRx intellectual property license to Sylentis for development and commercialization of RNAi Therapeutics (ALNY) 6.74 -0.19 : The co and Sylentis, S.A., a Spanish bio-pharmaceutical company announced that Alnylam has granted Sylentis a non-exclusive option for a new target-specific InterfeRx license. This license would enable the discovery, development, and commercialization of a synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. Sylentis' program is currently in a Phase I/II clinical trial. Upon Sylentis' exercise of this option, Alnylam would receive upfront and milestone payments, as well as royalties on sales of products covered by the licensing agreement. Additional financial details were not disclosed. Sylentis is a wholly owned subsidiary of Grupo Zeltia.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALNY News